-

AmerisourceBergen Elects Redonda Miller, M.D., to its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.

“We welcome Dr. Miller to the Board of Directors. Her experience as a healthcare leader and as a physician brings great perspective to AmerisourceBergen and our stakeholders,” said Jane E. Henney, M.D., Lead Independent Director.

“Dr. Miller’s healthcare and business experience will help support AmerisourceBergen as we live our purpose of being united in our responsibility to create healthier futures,” said Steven H. Collis, Chairman, President & Chief Executive Officer.

Dr. Miller has served as the president of The Johns Hopkins Hospital since 2016. Previously, she was Chief Medical Officer and Senior Vice President of Medical Affairs for The Johns Hopkins Health System. A practicing internist, Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a non-executive director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). In 2020, she was inducted into the National Academy of Medicine. In addition, she is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and a member of the Board of Directors of Turnaround Tuesday Inc.

Dr. Miller received her M.D. from The Johns Hopkins University School of Medicine, M.B.A. from The Johns Hopkins University, and B.S. from The Ohio State University.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our more than 43,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

Contacts

Bennett S. Murphy
610-727-3693
Senior Vice President, Investor Relations
bmurphy@amerisourcebergen.com

Industry:

AmerisourceBergen Corporation

NYSE:ABC
Release Versions
English

Contacts

Bennett S. Murphy
610-727-3693
Senior Vice President, Investor Relations
bmurphy@amerisourcebergen.com

More News From AmerisourceBergen Corporation

Covetrus and MWI Animal Health to Merge

CONSHOHOCKEN, Pa. & PORTLAND, Maine--(BUSINESS WIRE)--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform. “Our mission has always been to empower veterinary practices to work smarter and deliver better care,” said Ben Wolin, President and Chief Executive O...

Cencora Closes $3.0 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Se...

Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February...
Back to Newsroom